Golidocitinib by Dizal Pharmaceutical for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Golidocitinib (DZD-4205) is under development for the treatment of non-small cell lung cancer and T cell lymphomas including peripheral T cell lymphoma, vascular immunoblast type (AITL), Anaplastic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback